Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Zika virus vaccine-Themis (Primary)
- Indications Zika virus infection
- Focus Therapeutic Use
- Sponsors Themis Bioscience
- 10 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.